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ABSTRACT 
Identification of Molecules by Spectral Imaging  
by Qamar A. Alshammari 
 
Spectral imaging is a powerful technique which uses the wavelength to identify/quantify 
the exact location and amount of the molecules. It facilitates the identification of materials 
and studying their properties through analyzing the way they interact with light. The study 
of light interaction with elements is called spectroscopy; spectroscopy examines how light 
behaves in the target and recognizes materials based on their spectral signatures. Spectral 
signatures can be compared to fingerprints which can be used to identify a person; spectral 
signatures can be used to identify materials. Therefore, we hypothesize that identifying the 
exact location and quantity of molecules present in the given cells samples can be done by 
using a spectral imaging system. In this study, we identify the exact UV-Vis and 
fluorescence spectra of organic substances including Rhodamine 6G, Doxorubicin and 
UV-Vis spectra inorganic compounds including silver (Ag), gold (Au) nanoparticles (NPs). 
After that, we used the Q-TOF LC/MS system to quantify the maximum and minimum 
detectable concentrations of Rhodamine 6G and Doxorubicin by checking the chemicals 
spectrum based on the molecular weight. In addition, we used HPLC system to quantify 
the chemicals basing on their UV spectrum. Forwards, we used spectral imaging system to 
determine the exact amount and location of the molecules within cells samples. For 
Rhodamine 6G and doxorubicin, we started with the minimum detectable concentration by 
Q- TOF and consider it as a maximum limit with spectral imaging. And for NPs we used 
the maximum concentration for the analysis. Using the spectral imaging we were able to 
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detect the exact location of Rhodamine 6G which was in the cytoplasm, Doxorubicin in 
the nucleoplasm, and NPs in both. Furthermore, spectral imaging was able to detect much 
lower concentrations of Rhodamine 6G and Doxorubicin by the spectrum in comparison 
to Q-TOF LC/MS.    
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Chapter 1 
INTRODUCTION 
 
1.1. General Introduction 
Spectral imaging merges of two elements imaging and spectroscopy. The need to establish a three-
dimensional (3D) information which consists of various images of the same item, makes this 
merging not meaningless. While other imaging systems can give the intensity at a broad 
wavelengths, spectral imaging gives a spectrum at every pixel. This is a 3D informational 
collection and can be seen as a cube shape of data (Fig 1). Combining the features of imaging and 
spectroscopy is a superior way to understand the aspect of spectral imaging. Imaging is an 
innovative science of getting spatial and temporal information from items for the reason of 
collecting data. Right now, computerized imaging is the most developed and appropriate strategy 
where data are recorded utilizing an advanced camera, for example, a charged coupled device 
(CCD). In biologic examinations, the images can be estimated either by basic optical strategies, 
for example, optical microscopy or by further developed techniques like time-lapse imaging. The 
quality of an image decides the measure of information that can be extracted from it. The most 
basic parameters that describe the gained images: spatial resolution 250 nm (in-plane) at λ 500 nm, 
most reduced signal relies upon the quantum productivity of the detector (the higher the better). 
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1.2. Spectroscopy  
Spectroscopy, the study of securing and clarifying the spectral qualities of an object, is a science 
that has been generally studied for centuries. A spectrum is a collection of light intensities at 
various wavelengths. The structure of particles and atoms is specifically identified with 
spectroscopy. The spectrum is an immediate estimation of the energy levels of the defined 
structure. To quantify a spectrum, the light is scattered into its different wavelength (or color) 
elements, and the intensity at every wavelength is estimated. Most valuable features of a spectrum 
include spectral resolution 1–20 nm (may depend on λ) within spectral range of 400–900 nm. 
Spectral imaging approaches can be separated into the following techniques: (1) Wavelength-scan 
approaches that measure the pictures at one wavelength at any given moment. (2) Spatial-scan 
techniques that measure the entire spectrum of a part of the image at a time and scan the picture 
(e.g., line by line). (3) Time-scan methods that measure a set of images where every single one of 
Figure 1 Demonstrating of a spectral image data, each point in the cube clarify a single number. 
Because spectral image is explained as I(x,y,l), it can be observed as spectrum I(l) at every pixel 
I(x,y) or as an image I(x,y) at each wavelength I(l) 
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them is a superposition of spectral or spatial picture data. Toward the finish of the capturing, the 
information is converted to the real spectral image (e.g., by Fourier strategies) image (e.g., by 
Fourier strategies). (4) Approaches that measures the entire spectral picture at the same time, but 
accord on the number of points in the spectrum, the spatial resolution (Garini et al., 2006). 
 
1.3. Spectral Imaging Types 
Spectral imaging can be separated into multispectral imaging, hyperspectral imaging (HSI), and 
ultra-spectral imaging. Multispectral imaging system gathers information in few and generally 
noncontiguous wide spectral bands, estimated in micrometers or tens of micrometers, whereas HSI 
can collect hundreds of spectral bands. Ultra-spectral imaging system gathers considerably more 
data. One of the significant benefits of spectral imaging technique is that it can obtain reflectance, 
retention, or fluorescence spectrum for every pixel in the image, which can be utilized to 
distinguish the biochemical alteration of items that cannot be analyzed by conventional gray or 
color imaging techniques. As indicated by the electromagnetic hypothesis, diverse biochemical 
constituents regularly have distinctive spectral signatures or marks. These marks generally created 
by the associations amongst materials and electromagnetic waves, for example molecule vibration.  
(Li et al., 2013).  
 
1.4. Spectral Imaging Applications 
The biological and pathological differences in tissues and organs have a close connection with the 
spectra. Spectral aspects in various wavelength areas yield a detectable spectral signature, making 
pathological alteration observable. Along these lines, the spectral imaging method additionally can 
be reached out to the biomedical engineering field to evaluate the physiological status of living 
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tissues, since it can exploit the spatial connections among the diverse spectra in a neighborhood. 
This innovation opens new prospects for science by which researchers can recognize and evaluate 
the connections among biologically active molecules, analyze living life forms noninvasively, 
carry out histopathological and fluorescent analyses, and improve natural explaining of illnesses. 
This character makes it conceivable not exclusively to distinguish some physiological changes of 
organic tissues by their spectral marks, yet additionally for early conclusion of a few ailments since 
the states of the spectra yield data about natural samples (Li et al., 2013). To date, tissue 
fluorescence was an outstanding amongst other techniques for improving the customary 
endoscopic determination of gastrointestinal (GI) sores. Tissues are lighted with ultraviolet (UV) 
or short wavelength visible (VIS) light from a laser or separated light source. This kind of tissue 
fluorescence that can be seen in the tissues is called "autofluorescence." The chemical groups in 
charge of the autofluorescence are called "fluorophores". Each group of fluorophores is identified 
by unmistakable excitation and emission wavelength ranges. It is normal for a single excitation 
wavelength to energize numerous fluorophores. Tissues additionally contain chemical groups 
called "chromophores" that retain light without re-discharge of fluorescence. The retention is 
firmly wavelength dependent and may fundamentally adjust the in vivo fluorescence range visible 
at the tissue surface. The fundamental chromophore in the live tissues in the obvious wavelength 
(400–700 nm) is hemoglobin. While each fluorophore has a particular fluorescence spectrum, 
tissues have a blend of many fluorophores that appear at in various concentration and at various 
depth. Changes in the characteristic fluorescence of the tissue layers with illness are because of 
modifications in their biochemical organization (metabolic state, microenvironment). 
Furthermore, alterations in the layer thicknesses or the blood components lead to the fluorescence 
contrasts seen amongst normal and unhealthy tissues. These fluorescence contrasts might be 
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adequate to recognize ordinary and infected tissues. In this manner, one of the application example 
is the utilization of autofluorescence for identification of early malignancies or premalignant 
colonic sores is subject to a changes in at least one of the accompanying components: (a) the tissue 
construction (mucosal thickening); (b) the light retention and scattering aspect at every layer, (c) 
the dispersion and concentration of fluorophores in the distinctive layers; (d) the biochemical 
microenvironment of the tissue, that may modify the fluorescence output or spectral form 
(DaCosta et al., 2007).  
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Chapter 2  
METHODOLOGY 
 
2.1. Materials  
The chemicals in this project include: anhydrous methanol HPLC grade (99.8%) and acetonitrile 
HPLC grade (≥ 99.9%) were purchased from SIGMA-ALDRICH, Rhodamine 6G (MW: 479.01 
g/mol) from SIGMA. Doxorubicin (MW: 579.98 g/mol) was obtained from TCI AMERICA. 
Trifluoroacetic Acid (TFA) from EMD Millipore Corporation, Formic Acid, and sucrose from 
Fisher Scientific (Fair Lawn, NJ). LL-CPK1 (ATCC® CL101.1TM) porcine renal epithelial cells 
from proximal tubule were obtained from American Type Culture Collection (ATCC; Manassas, 
VA). Trypsin, penicillin-streptomycin solution, Phosphate Buffered Saline (PBS) and Dulbecco's 
Modified Eagle Medium (DMEM) were purchased from Corning (Manassas, VA). Fetal bovine 
serum (FBS) was obtained from Seradigm (Logan, UT). Paraformaldehyde (PFA) from Electron 
Microscopy Services (Hatfield, PA) and Mounting Media HistoChoiceÒ from AMRESCO.  
 
2.2. Cell culture 
LL-CPK1 cells were cultured to a confluent monolayer in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin at 
37°C in 5% CO2 and 95% humidity. Cells were trypsinized (using a 0.05% solution of trypsin) 
regularly for passage when reached 70-90% confluence. For this research, cells were cultured to 
reach 70-80% confluence before treated with the chemicals.  
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2.3. UV-VIS and Fluorescence Spectrum Detection  
SpectraMax M5 Spectrophotometer was used to read the UV visible spectrum for doxorubicin, 
rhodamine 6G, silver (Ag) and gold (Au) nanoparticles (NPs). In addition, it was used to read the 
fluorescence spectrum for doxorubicin and Rhodamine. Table 1 describes the concentrations of 
the chemicals used in this method. Doxorubicin and Rhodamine were prepared at the same 
concentrations in methanol. Whereas Ag and Au NPs were diluted in Milli-Q water at different 
concentrations. The wavelength range of 200 – 800 nm was used to read UV spectrum for all 
chemicals. The fluorescence spectrum range was 400 - 800 nm for Doxorubicin and Rhodamine.  
 
 
 
 
  
Spectrum 
Detection 
Doxorubicin Rhodamine 6G Ag NPs Au NPs 
UV-VIS 1, 0.75, 0.5, 0.25, 
0.1 µM 
1, 0.75, 0.5, 
0.25, 0.1 µM 
100, 37.5, 25, 
12.5, 5 mg/mL 
100, 37.5, 25, 12.5, 
5 mg/ml 
Fluorescence 1, 0.75, 0.5, 0.25, 
0.1 µM 
1, 0.75, 0.5, 
0.25, 0.1 µM 
--- --- 
Table 1. Different concentrations of the chemicals were prepared to read the UV-VIS and 
fluorescence spectrums by spectrophotometer. Methanol was used to prepare the stock solutions 
of Doxorubicin and Rhodamine 6G at concentrations of 0.2 mM and 0.3 mM respectively. While 
Ag and Au NPs were diluted with Milli-Q water at different concentrations. 
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2.3. Detection and Quantification of Mass Spectrometry and UV Detection Limits  
Quadruple Time of Flight Liquid Chromatography / Mass Spectrometry (Q-TOF LC/MS) (Bruker 
Impact II™ and Ultimate 3000 UPLC (Dionex) was used to detect and quantify the maximum and 
lower detection limits based on the mass spectra for both Doxorubicin and Rhodamine 6G. MS 
method was performed by direct injection of different concentrations of Doxorubicin and 
Rhodamine (Table 2), between every single injection, methanol HPLC grade was used to wash the 
LC tubing. For Q-TOF LC/MS method, Doxorubicin was prepared at different concentrations 
(Table 2) and eluted by using gradient of solvent (A) 0.1% formic acid in Milli-Q water and (B) 
0.1% formic acid in acetonitrile. The flow rate was 0.3 mL/min, and the injection volume was 50 
µL with a total acquisition time of 10 min. The reversed phase-high liquid chromatography (RP-
HPLC) C18 column (Shimadzu 50 ´ 4.6mm, 3µm particle size) was used in the analysis. (Table 
3) In addition, Rhodamine was also prepared at different concentrations (Table 2) and analyzed by 
using the isocratic elution method in 100% methanol and an injection volume of 50 µL (Fig 2). 
However, to quantify the limits of Doxorubicin and Rhodamine in the UV spectrum wavelength, 
analytical Hitachi HPLC was use. The gradient elution was conducted using mobile phase (A) 
0.1% trifluoroacetic acid in Milli-Q water and (B) 0.1% trifluoroacetic acid in acetonitrile with the 
same gradients of Q- TOF method for Doxorubicin as shown in Table 3. Rhodamine was also 
analyzed with the isocratic method that has been used in Q- TOF.  
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Method Rhodamine 6G Doxorubicin 
Q-TOF MS 5.0, 3.0, 2.5, 2.0, 1.5, 1.0, 
0.5, 0.3, 0.2 nM. 
5.0, 3.0, 1.5, 1µM, 500, 450, 
300, 150 nM. 
Q- TOF LC/MS 5.0, 3.0, 2.5, 2.0, 1.5, 1.0, 
0.5, 0.3, 0.2 nM. 
5.0, 3.0, 1.0µM, 500, 300, 150 
nM. 
HPLC-UV 5.0, 3.0, 2.5, 2.0, 1.5, 1.0, 0.5, 0.3, 0.2 nM. 
5.0, 3.0, 1.0µM, 500, 300, 150 
nM. 
Time (min) % A % B Flow Rate (mL/min) 
0 95 5 0.3 
0 95 5 0.3 
1.5 95 5 0.3 
6 5 95 0.3 
7 5 95 0.3 
7.1 95 5 0.3 
9 95 5 0.3 
Table 3. RP-HPLC gradient for the separation of doxorubicin. 
 
Table 2. Rhodamine 6G and doxorubicin detectable concentrations for quantifying the mass 
and UV spectra by Q- TOF and HPLC.  
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Figure 2. The sequence of steps for Q-TOF LC/MS. 
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2.4. Cell Treatment  
Cells were seeded into sterilized 22x22 mm coverslip (globe Scientific Inc), in 6 well plate 
(Greiner bio-one CELLSTARâ, total volume of 2 mL at each well) under normal growth 
conditions until reached 70–80% confluency. The cells then were treated with 100 µL of the 
selected chemical at different concentrations ranging from 150 to 1 nM for Doxorubicin, 100 µM 
to 0.01 nM for Rhodamine 6G and 100 mg/mL for NPs (Table 4). The cells were treated for a total 
incubation time of 18 hrs. Then, cells were fixed for 10 min in fixing solution (2.5 mL PFA, 7.5 
mL PBS and 0.2 g sucrose) at room temperature; afterward, cells were washed 3 times with PBS 
5 min each time. After that, the coverslip was placed on the slide that contains 25 µL of Mounting 
Media overnight at room temperature (Fig 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The sequence of steps for the cells treatments and analysis for spectral imaging. 
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2.5. Spectral Imaging  
Spectral imaging instrument (ASI Spectral Imaging System, OLYMPUS) was used in this research. 
Manual image acquisition was conducted with 60× magnification fields. For spectral imaging data, 
the pure doxorubicin, rhodamine 6G, Ag and Au NPs spectral wavelengths were identified at the 
beginning. Then, we uploaded these spectrums as libraries for further cells analysis. Subsequently, 
images of the cells that treated with chemicals were captured randomly by using SKY and 
brightfield filters at least 10 capturing at each concentration. Afterward, we analyzed the captured 
image by using spectrum libraries of the chemicals and scanned all the interesting area to obtain 
the location that matched with spectrum wavelength library (Fig 4).  
  
Spectral Imaging Doxorubicin Rhodamine 6G NPs 
Concentrations 150, 100, 10, 1 nM 100 µM, 0.2, 0.08, 
0.01 nM 
100mg/mL 
Table 4. Selected chemical concentrations for spectral imaging 
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2.6. Statistical Analysis 
Most of our statistical analysis was conducted by using Spectral Imaging software version 
7.2.7.34276 and GraphPad Prism software version 8.0. Microsoft Excel software version 16 was 
also used for linear regression analysis to obtain a standard calibration curve and linear equation.  
Comparisons between two groups were analyzed with two-tailed student-t tests. Comparisons of 
three or more groups were done using ANOVA analysis followed by a posthoc test. BioRender 
software was also used to draw the figures in this research.  
Figure 4. The sequence of steps for the spectral imaging data acquisition.	
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Chapter 3 
RESULTS AND DISCUSSION 
 
3.1. Spectrophotometer 
The UV Spectra of Rhodamine 6G with concentration range 1 – 0.1 µM show excitation at ~ 530 
nm, which was compared with previous studies and showed consistent results (Fig 5b). Using the 
scanning spectrophotometer we obtained a wavelength of fluorescence emission spectrum at ~580 
nm, which is also consistent with previous researches (Chapman et al., 2016) (Fig 5a). We further 
conducted a linear regression analysis to evaluate the validity and the linearity of the concentration-
dependent data. The relationships displayed in the scatterplots in Fig 6a and b of the coefficient of 
determination (R2) of rhodamine 6G is linear between intensities at different concentrations and 
the wavelengths, at R2= 0.99 and 0.95 for excitation and emission spectrum respectively. 
Doxorubicin excitation wavelength was found at ~483 nm for concentrations range 1 – 0.1 µM, 
which is consistent with previous studies (Liang et al., 2018) (Fig 7a).  At the same concentrations, 
fluorescence emission wavelength was found ~592 nm (Fig 7b). In addition, linear regression 
analysis was conducted for excitation and emission spectrum data points. In the scatterplots in Fig 
8a and b, the data point relationships showed linearity between intensities and the wavelengths at 
different concentrations of excitation and emission spectrum, at R2= 0.96 and 0.89 respectively.  
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Figure 5. (a) Fluorescence emission wavelength of Rhodamine 6G with methanol at ~ 580 nm with each 
concentration. (b) Spectrophotometer excitation wavelength of Rhodamine 6G with methanol at ~ 530 
nm with each concentration. The lower graphs of a and b are the enlarged scale of the area interested. 	
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Figure 8. (a) Linear regression analysis of Doxorubicin excitation wavelength. X= concentrations 
range from 1 – 0.1 µM, y= average of intensities. (b) Linear regression analysis of Doxorubicin 
emission wavelength. X= concentrations range from 1 – 0.1 µM, y= average of intensities.	
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Further, Ag and Au NPs were scanned via spectrophotometer in 200 – 400 nm. AuNPs excitation 
wavelength was found at ~536 nm which is consistent with the expectation of  previous researchers 
(between 520 and 580 nm, Haiss, Thanh, Aveyard, & Fernig, 2007) (Fig 9a). As well as Ag NPs 
excitation wavelength at ~ 420 nm that is also consistent with previous studies (Fayaz et al., 2010)  
(Fig 9b). In addition, linear regression analysis was perfumed for NPs.  As shown in Fig 10a and 
b the scatterplots of NPs, there is a linear relationship between intensities and the wavelength at 
different concentrations of Au and AgNPs at R2= 0.94, 0.97 respectively.  
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Figure 9. (a) Spectrophotometer excitation wavelength of gold NPs with Milli-Q water at ~ 536 nm 
with each concentration. (b) Spectrophotometer excitation wavelength of silver NPs with Milli-Q water 
at ~ 420 nm with each concentration. The lower graphs of a and b are the enlarged scale of the area 
interested. 
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Figure 10. (a) Linear regression analysis of silver NPs excitation wavelength. 
X= concentrations range from 100 – 5 mg/mL, y= average of intensities. (b) 
Linear regression analysis of gold NPs excitation wavelength. X= 
concentrations range from 100 – 5 mg/mL, y= average of intensities. 
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b. 
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3.2. Q- TOF MS and LC/MS  
To quantify the maximum and minimum mass spectrometry concentrations limits of the selected 
chemicals, Q-TOF MS and LC/MS was conducted. For Q-TOF MS method, Rhodamine was by 
injected at different concentrations (Table 2) and by checking the molecular mass the maximum 
concentration limit to detect at 5 nM (Fig 11), while 0.2 nM is the minimum concentration with 
precursor ion at m/z 443 Da which consistent with previous studies (Ferreira et al., 2017)  (Fig 12). 
Linear regression analysis was performed to check the validity of our MS data point. The 
scatterplot in Fig 13 showed the relationship between intensities and different concentrations at 
m/z 443 Da of MS data. There is linear relationship result between the MS data particularly from 
0.2 to 2 nM at R2= 0.9, from 2.5 to 5 nM the line becomes flat which it might be considering a 
sign of saturation.  Furthermore, Q- TOF LC/MS was performed for Rhodamine at the same 
concentrations as Q-TOF MS method. The detection of LC/MS data was done by using 3 µm 
column via checking the molecular mass of the chemical at each concentration. The maximum and 
minimum concentrations of detectable limits of Rhodamine concentration were consistent with 
MS data, at 5 – 0.2 nM respectively (Fig 14, 15). The linear analysis also conducted on Q- TOF 
LC/MS data, and it showed a good linearity relationship between the area under the curve (AUC) 
of the intensities vs. concentrations, R2= 0.98 (Fig 16). For a better comparison between spectral 
imaging and LC/MS data, UV quantification of Rhodamine 6G was also performed by using 
analytical HPLC. The limits concentrations detectable for rhodamine 6G UV peaks (at 530 nm) 
were consistent with Q- TOF MS and LC/MS data which at 5 – 0.2 nM (Fig 17, 18). The linearity 
of AUC for UV peaks and intensities shown in Fig 19, our data point showed a good linearity (R2= 
0.98) but because we set all the data at zero, it gave a lower linear relationship (R2= 0.66) in 
comparing with Q- TOF MS and LC/MS data.  
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Figure 11. Q- TOF MS result for direct injection of Rhodamine 6G at the concentration of 5 nM 
(which is considered to be the maximum concentration limit), precursor ion at m/z 443 Da. 
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Figure 12. Q- TOF MS result for direct injection of Rhodamine 6G at the concentration of 0.2 nM 
(which is considered to be the minimum concentration limit), precursor ion at m/z 443 Da. 
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Figure 13. Linear regression analysis of Rhodamine Q-TOF MS data. X= 
concentrations range from 5 – 0.2 nM, y= average of intensities of m/z 443 Da. 
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Figure 14. Q- TOF LC/MS result for the AUC of Rhodamine 6G at the concentration of 5 nM 
(which is considered to be the maximum concentration limit), precursor ion at m/z 443 Da. 
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Figure 15. Q- TOF LC/MS result for the AUC of Rhodamine 6G at the concentration of 0.2 nM 
(which is considered to be the minimum concentration limit), precursor ion at m/z 443 Da. 
 
27 
 
  
y = 11.182x + 6.3132
R² = 0.9815
0
10
20
30
40
50
60
70
0 1 2 3 4 5 6
A
U
C
. (
x1
,0
00
,0
00
) 
Concentration (nM) 
Figure 16. Linear regression analysis of Rhodamine Q-TOF LC/MS AUC 
data. X= concentrations range from 5 – 0.2 nM, y= average of intensities of 
m/z 443 Da. 
 
28 
 
  
Figure 17. Analytical HPLC chromatograph result for the AUC of Rhodamine 6G at the concentration of 
5 nM (which is considered to be the maximum concentration limit), the UV detection at 530 nm. 
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Figure 18. Analytical HPLC chromatograph result for the AUC of Rhodamine 6G at the concentration of 
0.2 nM (which is considered to be the minimum concentration limit), the UV detection at 530 nm. 
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Figure 19. Linear regression analysis of rhodamine HPLC - UV AUC data. X= 
concentrations range from 5 – 0.2 nM, y= average of intensities of 530 nm. 
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Doxorubicin Q- TOF MS and LC/MS were also conducted to quantify the maximum and minimum 
mass spectrometry concentrations detectable limits and further compare it with the spectral 
imaging system. Doxorubicin was directly injected at different concentrations (Table 2) for Q- 
TOF MS analysis. By checking the molecular mass the maximum concentration limit to detect was 
determined at 5 µM (Fig 20), while the minimum detection limit is 150 nM (Fig 21). The precursor 
ion was found at m/z 544 Da which is consistent with previous researches (Sottani, Poggi, 
Melchiorre, Montagna, & Minoia, 2013). Linear regression analysis was done to check the validity 
of the Q-TOF MS data. The relationship between different concentrations at m/z 544 Da and the 
intensities of MS data is showing in the scatterplot in Fig 22. Linear relationship results between 
the MS data especially from 150 nM to 1 µM at R2= 0.86, from 1.5 to 5 µM the line starts to 
become flat which could be considered a sign of saturation.  Also, at the same concentrations of 
Q- TOF MS method, doxorubicin was prepared to perform Q- TOF LC/MS analysis. The detection 
of the data was conducted by using a 3 µm column through testing the molecular mass of the 
chemical at each concentration. The maximum and minimum concentrations detectable limits were 
consistent with MS data, at 5 µM – 150 nM respectively (Fig 23, 24). Linear consideration was 
conducted on Q- TOF LC/MS, it showed an excellent linearity relationship between the intensities 
and AUC of the concentrations, R2= 0.99 (Fig 25). At the same way of Rhodamine, analytical 
HPLC analysis was performed for UV quantification of Doxorubicin in order to compare spectral 
imaging and LC/MS data. Doxorubicin UV peaks for the detectable concentrations limits (at 483 
nm) were consistent with Q- TOF MS and LC/MS data which at 5 µM – 150 nM (Fig 26, 27). The 
linearity of the intensities and AUC- UV peaks are shown in the scatter plot, the result here also 
represent an excellent linear relationship between our data point (R2= 0.99) (Fig 28).  
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Figure 20. Q- TOF MS result for direct injection of Doxorubicin at the concentration of 5µM (which is 
considered to be the maximum concentration limit), precursor ion at m/z 544 Da.	
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Figure 21. Q- TOF MS result for direct injection of Doxorubicin at the concentration of 150 nM 
(which is considered to be the minimum concentration limit), precursor ion at m/z 544 Da.	
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Figure 22. Q- TOF MS Linear regression analysis of Doxorubicin data. X= 
concentrations range from 5 µM – 150 nM, y= average of intensities of m/z 544 
Da. 
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Figure 23. Q- TOF LC/MS result for the AUC of Doxorubicin at the concentration of 5 µM (which is 
considered to be the maximum concentration limit), precursor ion at m/z 544 Da.	
 
36 
 
Figure 24. Q- TOF LC/MS result for the AUC of Doxorubicin at the concentration of 150 nM (which is 
considered to be the minimum concentration limit), precursor ion at m/z 544 Da.	
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Figure 25. Q- TOF LC/MS AUC linear regression analysis of Doxorubicin data. X= 
concentrations range from 5 µM – 150 nM, y= average of intensities of m/z 544 Da. 
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Figure 26. Analytical HPLC chromatograph result for the AUC of doxorubicin at the concentration of 5µM 
(which is considered to be the maximum concentration limit), the UV detection at 483 nm.	
 
39 
 
	 	
Figure 27. Analytical HPLC chromatograph result for the AUC of doxorubicin at the concentration of 150 
nM (which is considered to be the minimum concentration limit), the UV detection at 483 nm.	
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Figure 28. Linear regression analysis of doxorubicin HPLC - UV AUC data. X= concentrations range 
from 5 µM – 150 nM, y= average of intensities of 483 nm.	
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3.3 Spectral Imaging  
3.3.1 Rhodamine Spectral Imaging result 
The spectral imaging measurements were conducted by using SKY filter for pure rhodamine 6G 
fluorescence wavelength at ~ 580 nm which was detected using spectrophotometer. However, pure 
Rhodamine (dye alone) with spectral imaging system gives an additional wavelength peak at ~ 
670 nm which we didn’t identified yet (Fig 29b). These wavelengths were uploaded and saved as 
libraries for further treated cell analysis.  
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Figure 29. (a) Pure Rhodamine 6G brightfield image by using brightfield filter, spectral image by using 
SKY filter which represents the uploaded Rhodamine library analysis and merged image which is merged 
between brightfield and spectral images. (b) The graph represents pure Rhodamine 6G fluorescence 
wavelength at ~ 580 nm, 670 nm, X= wavelengths (580, 670 nm) and Y= signal intensity. Inside represents 
the area that contains brighter fluorescence dye and higher intensity in comparing with the peripheral zone, 
while background showed the wavelength of the background area of rhodamine. (c) The bars showed the 
intensity variation of the data point for peak1 which is higher than peak2. 
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Fig 29a showed the brightfield image of pure Rhodamine obtained by using brightfield filter, a 
spectral image which was done by using SKY filter. Its represent the uploaded wavelength library 
analysis, and merged image that merged between brightfield and spectral images. The graph in Fig 
29b represents different fluorescence wavelengths of pure rhodamine 6G at ~ 580 nm, 670 nm. 
The inside showed the area that has brighter fluorescence dye and higher wavelength intensity in 
comparison to the peripheral area, background showed the wavelength intensity of the chemical 
background. In addition, the bars (Fig 29c) illustrate the intensity data point variation of peak1 
which is higher than peak2. Furthermore, analysis of the cell that treated with rhodamine 6G was 
also conducted in this research. Cells were treated at different concentrations starting with 0.2 nM 
as the minimum concentration detectable by Q- TOF (Table 4) for 18 hrs and then the cells were 
fixed for spectral imaging analysis. Fig 30a represented the brightfield, spectral and merged images 
of the negative control which is untreated cells. Fig 30b showed the difference between cytoplasm 
and nucleoplasm wavelength which are considered to be background in compare with the positive 
control (pure dye). In order to show the saturation area inside the cells, 100 µM of Rhodamine 6G 
was used to treat the cells for 18 hrs. Fig 31a showed the brightfield image, a spectral image (by 
using SKY filter) which is the result of the uploaded libraries of pure Rhodamine and merged 
images of the cells that treated with 100 µM of the dye. The spectral image also showed the 
rhodamine location in the cell which is specified in the cytoplasm. Fig 31b illustrates different 
fluorescence wavelengths of 100 µM treated cells at ~ 580 nm, 670 nm, which are consistent with 
pure dye results. However, there is an additional small peak at ~ 530 nm which we didn’t identify 
it yet. Blue wavelength represented the cytoplasm rhodamine spectrum, and red wavelength 
showed the spectrum of rhodamine in the cell nucleoplasm. The bars (Fig 31c) illustrate the 
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intensity data point diversity of peak1 which is higher than peak2, and this diversity was consistent 
with peaks variations of the pure rhodamine.  
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Figure 30. (a) Negative control of the untreated cells brightfield image by using brightfield filter, 
spectral image by using SKY filter and merged image which is merged between brightfield and spectral 
images. (b) The graph represents negative control fluorescence wavelengths which are considered to 
be a background in comparing with the positive control, X= wavelengths and Y= signal intensity. (c) 
The bars showed the intensity variation of the data point for untreated cells. 
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Figure 31. (a) Brightfield image of treated cells with 100 µM of Rhodamine 6G image by using 
brightfield filter, spectral image by using SKY filter which represented the result of uploaded 
Rhodamine library and the saturation area is showing in the lower left part of the image. The 
spectral image also showed the rhodamine location in the cell which is specified in the cytoplasm. 
The merged image which is a combination of brightfield and spectral images. (b) The graph 
represented Rhodamine 6G fluorescence wavelength at ~ 580 nm, 670 nm inside the cells, X= 
wavelengths and Y= signal intensity. The blue wavelength shows the area that contains Rhodamine 
fluorescence which is in the cytoplasm, while the red wavelength represents the spectrum of the 
area in the cell nucleoplasm. (c) The bars showed the intensity variation of the data point for peak1 
which is higher than peak2, and this variation in consistent with pure dye data pint results. 
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Forward, we treated the cells with 0.2 nM of rhodamine which is considered to be the maximum 
limit to detect this dye in comparison with Q- TOF. Fig 32a demonstrated the brightfield image, 
spectral image which is the result of the uploaded libraries of pure Rhodamine and merged images 
of the cells that treated with 0.2 nM of the dye. Fig 32b showed different fluorescence wavelengths 
of 0.2 nM treated cells at ~ 580 nm, 670 nm, which are consistent with pure and 100 µM dye 
results. The blue wavelength represents the cytoplasm spectrum of Rhodamine and red wavelength 
showed the spectrum of the cell nucleoplasm. The bars in Fig 32c explained the variety of intensity 
data point of peak1 which is higher than peak2, and this variation consistent with peaks variations 
of the pure and 100 µM rhodamine results. In addition, the intensities at this concentration become 
lower than pure and 100 µM Rhodamine samples which are expected since we prepare lower 
concentrations. Since rhodamine can be detectable at a concentration of 0.2 nM, we treated cells 
with much lower concentration at 0.08 nM. Fig 33a showed the brightfield image by brightfield 
filter, spectral image which is the result analysis of the uploaded libraries of pure Rhodamine (the 
system also showed rhodamine location in the cell which is in the cell cytoplasm) and merged 
images of the cells that were treated with 0.08 nM of the dye. Fig 33b demonstrated different 
fluorescence wavelengths of 0.08 nM treated cells at ~ 580 nm, 670 nm, which are consistent with 
pure, 100 µM and 0.2 nM dye results. Blue wavelength clarifies the cytoplasm spectrum of 
Rhodamine and red wavelength showed the spectrum of the nucleoplasm of the sample. The bars 
in Fig 33c interpreted the data point intensity variation of peak1 which is higher than peak2, this 
variation consistent with peaks variations of the pure, 100 µM and 0.2 nM Rhodamine results.  
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Figure 32. (a) Cells treated with 0.2 µM of Rhodamine 6G brightfield image by using brightfield 
filter, spectral image by using SKY filter which represented the result of uploaded rhodamine 
library and merged image which is a combination of brightfield and spectral images. (b) The graph 
represented Rhodamine 6G fluorescence wavelength at ~ 580 nm, 670 nm inside the cells, X= 
wavelengths and Y= signal intensity. The blue wavelength explained the area that contains 
Rhodamine fluorescence which is in the cytoplasm, while red wavelength showed the spectrum 
of the area which was in cell nucleoplasm. (c) The bars showed the intensity variation of the data 
point for peak1 which is higher than peak2, and this variation in consistent with pure dye data pint 
results. The intensities here become lower in comparing with pure and 100 µM rhodamine since 
we prepared lower concentration. 
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Figure 33. (a) Brightfield image of the cells that treated with 0.08 µM of Rhodamine 6G by using 
brightfield filter, spectral image by using SKY filter which represented the result of uploaded 
Rhodamine library and merged image which is a combination of brightfield and spectral images. 
(b) The graph represented Rhodamine 6G fluorescence wavelength at ~ 580 nm, 670 nm inside 
the cells, X= wavelengths and Y= signal intensity. The blue wavelength showed the area that 
contains Rhodamine fluorescence which is in the cytoplasm, while red wavelength explained the 
spectrum of the cell nucleoplasm. (c) The bars illustrated the data point intensity variation of 
peak1 which is higher than peak2, this variation consistent with peaks variations of the pure, 100 
µM and 0.2 nM rhodamine results. The intensities here become lower in comparing with pure and 
100 µM rhodamine since we prepare lower concentration. 
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Then, we treated cells with 0.01 nM of rhodamine for further analysis. Fig 34a interpreted the 
brightfield image which has been done by brightfield filter, a spectral image which is considered 
to be the result analysis of the uploaded libraries of pure Rhodamine. The spectral image also 
illustrates the dye location in the cell which is in the cytoplasm. The merged image is a combination 
of spectral and brightfield images of 0.01 nM Rhodamine. Fig 34b showed different fluorescence 
wavelengths of 0.01 nM treated cells at ~ 580 nm, 670 nm, which are consistent with pure, 100 
µM, 0.2 and 0.08 nM dye results. The blue wavelength illustrated the spectrum of cytoplasm which 
contains rhodamine, and the red wavelength showed the spectrum of the cell nucleoplasm. The 
bars in Fig 34c demonstrated the diversity of intensity data point of peak1 which is higher than 
peak2, this variety consistent with peaks variations of the pure, 100 µM 0.2 and 0.08 nM 
rhodamine data. The intensities here become much lower in compare with higher concentration 
points. Therefore, 0.01 nM consider being be the minimum detectable concentration of rhodamine 
6G by the spectral imaging system in comparing with 0.2 nM which is the minimum concentration 
to detect by Q- TOF system.  Furthermore, we conducted a linear regression analysis to check the 
validity of our data point of Rhodamine 6G. Fig 35a represented the linearity result of the average 
intensities of peak 1 vs log of different concentrations in M, the data showed a good linear 
relationship result at R2= 0.85. Therefore, we can consider it as a stander peak for Rhodamine in 
this research. While Fig 35b illustrated the linear relationship between the average intensities of 
peak 2 and the log of concentrations in M, it showed less linearity in comparing with peak 1 at R2= 
0.72. Fig 35c demonstrated the linearity of the ratio of average intensities for peak 1/peak 2, the 
linear relationship between these data point is less in comparing with peak 1 and peak 2 at R2= 
0.17. 
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Figure 34. (a) Cells treated with 0.01 µM of Rhodamine 6G brightfield image by using brightfield 
filter, spectral image by using SKY filter which clarified the result of uploaded Rhodamine library 
and merged image of both brightfield and spectral images. (b) The graph showed Rhodamine 6G 
fluorescence wavelength at ~ 580 nm, 670 nm in the cells, X= wavelengths and Y= signal 
intensity. The blue wavelength described the area that has Rhodamine fluorescence which is the 
cytoplasm, while red wavelength demonstrated the spectrum of the nucleoplasm. (c) The bars 
interpret the data point intensity variation of peak1 which is higher than peak2, this diversity 
consistent with peaks variations of the pure, 100 µM, 0.2 and 0.08 nM Rhodamine data. The 
intensities here also become lower in comparing with higher concentrations of rhodamine. 
Therefore, 0.01 nM consider being be the minimum detectable concentration of rhodamine by 
spectral imaging.  
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Figure 35. Linear regression analysis of Rhodamine 6G data by spectral imaging. X= log 
of concentrations in M, Y= average of signal intensity. (a) The graph represented the average 
intensities of peak 1 ( ~ 580 nM) vs the concentrations, and here we can consider peak 1 
because of its show good linearity at R2= 0.85. (b) This graph demonstrated the peak 2 
average intensities, it showed less linearity in comparing with peak 1 at R2= 0.72. (c) 
illustrated the ratio of average intensities for peak 1/peak 2, which has less linearity in 
comparing with peak 1 and peak 2 at R2= 0.17. 
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3.3.2. Doxorubicin Spectral Imaging Result 
Since spectral imaging system was able to identify the amount and location of Rhodamine 6G 
within cell samples, we further tested another chemical with the same approach. To check pure 
Doxorubicin fluorescence wavelength, spectral imaging was conducted by using SKY filter to 
have the spectrum at ~ 592 nm which is consistent with the spectrophotometer fluorescence 
spectrum. However, an additional wavelength peak at ~ 670 nm also appears with Doxorubicin 
which we didn’t identify this peak yet (Fig 36b). For cell analysis, these wavelengths were 
uploaded and saved as libraries files. As shown in Fig 36a brightfield filter was used to capture 
brightfield image of pure Doxorubicin, used SKY filter to capture the spectral image, it represent 
the analysis of uploaded wavelengths library and merged image that combined between brightfield 
and spectral images. The graph in Fig 36b illustrated pure Doxorubicin fluorescence wavelength 
at ~ 592 nm, 670 nm. The inside interprets the area that contains higher wavelength intensity based 
on brighter chemical fluorescence in comparing with the peripheral area which contains less. The 
background showed the wavelength intensity of the chemical background area, which should be 
any spectrum but not doxorubicin spectrum. In addition, the bar graph Fig 36c showed the variety 
of intensity data point result of peak1 which is higher than peak2. Next, we treated the cells with 
different concentrations of Doxorubicin, starting with 150 nM since it was the maximum 
detectable concentration limit by Q- TOF. Fig 37a displayed the negative control images which 
are untreated cells, starting with brightfield image by brightfield filter, spectral image by SKY 
filter and merged images. Fig 37b showed wavelength differences between cytoplasm and 
nucleoplasm which reflect the background in comparing with the positive control (pure 
Doxorubicin).  
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Figure 36. (a) Brightfield image of pure Doxorubicin by using brightfield filter, spectral image 
by using SKY filter which exemplified the analysis of uploaded library and merged image which 
combines between brightfield and spectral images. (b) The graph demonstrated the fluorescence 
wavelength of pure Doxorubicin at ~ 592 nm, 670 nm, X= wavelengths, and Y= signal intensity. 
Inside showed the area that covers higher intensity and brighter chemical fluorescence in 
comparing with the peripheral zone whereas background displayed Doxorubicin wavelength of 
the background region. (c) The bar graph exhibited the variation of the intensity data point result 
for peak1 which is higher than peak2. 
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Figure 37. (a) Untreated cells which are considered to be the negative control in the study. The 
brightfield image captured by using brightfield filter, spectral image by using SKY filter and 
merged image which combined between brightfield and spectral images. (b) The graph illustrated 
the fluorescence wavelengths of the negative control which reflect the background in comparing 
with positive control. X= wavelengths and Y= signal intensity. (c) The bars indicated the data 
point of the intensity variation for untreated cells. 
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Cells treated with 150 nM of Doxorubicin are shown in Fig 38a as brightfield image which was 
taken with brightfield filter, spectral image by SKY filter which is the result of the uploaded 
libraries of pure Doxorubicin and merged of brightfield and spectral images. The spectral image 
revealed Doxorubicin location in the cell which is specified in the nucleoplasm. Fig 38b exhibited 
different fluorescence wavelengths of 150 nM treated cells at ~ 592, 670 nm, which are consistent 
with the pure chemical results. However, there is an additional small peak at ~ 520 and we didn’t 
yet identify this peak. The blue wavelength represents the nucleoplasm spectrum of Doxorubicin, 
and red wavelength showed the background spectrum which is cell cytoplasm. The bar graph in 
Fig 38c illustrated the variety of intensity data point results of peak1 which is higher than peak2, 
this variety consistent with peaks variations of the pure Doxorubicin. Furthermore, we treated cells 
with lower concentrations of Doxorubicin, 100 nM Fig 39, 10 nM Fig 40 and 1 nM fig 41. At all 
of these figures, (a) represented the brightfield image that captured by brightfield filter, a spectral 
image which is the results of uploaded library analysis done by using SKY filter and merged image 
which is combine between spectral and brightfield images. (b) The graph showed different 
wavelength intensities of 592 and 670 nm based on the location. The blue spectrum displayed the 
area that has Doxorubicin in the sample, and the red spectrum exhibits the background region 
which is cytoplasm. (c) The bars explained the intensity data point variation for peak 1 that is 
higher than peak 2, the variation consistent with pure, 150 nM of doxorubicin. In general, within 
cell samples, the intensities become lower at each concentration 150 – 1 nM in comparing with 
pure Doxorubicin. 
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Linear regression analysis performed to check the validity of our data point of Doxorubicin. Fig 
42a showed the linearity result of the average intensities of peak1 vs log of different 
concentrations, the data displayed an excellent linear relationship result at R2= 0.93. Therefore, we 
can consider it as a standard peak for Doxorubicin in this study. While Fig 42b demonstrated the 
linear relationship between the average intensities of peak 2 and the log of concentrations. It 
displayed less linearity in comparison with peak 1 at R2= 0.76. In addition, Fig 43a illustrated the 
linearity of the ratio of average intensities for peak 1/peak 2, the linear relationship between these 
data point is less as compared with peak1 and peak2 at R2= 0.62. The graph in Fig 43b showed the 
percentage of the abnormal cells (specifically abnormal nucleoplasm) of the samples, this done by 
counting the abnormal nucleoplasm at each sample image, the percentage of the abnormality 
increases with higher concentrations of Doxorubicin.  
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Figure 38. (a) Brightfield image of the cells which are treated with 150 nM of Doxorubicin by 
using brightfield filter, spectral image by using SKY filter which displayed the result of uploaded 
doxorubicin library and merged image of brightfield and spectral images. (b) The graph represented 
Doxorubicin fluorescence wavelength at ~ 592 nm, 670 nm inside the cells, X= wavelengths and 
Y= signal intensity. The blue wavelength shows the region that contains Doxorubicin fluorescence 
which is in the nucleoplasm, whereas red wavelength illustrated the spectrum of the background 
area which is cell cytoplasm. (c) The bar graph explained the intensity data point variety for peak1 
which is higher than peak2 and this variation in consistent with pure Doxorubicin data results. The 
intensities here become lower in comparing with pure Doxorubicin since we prepared lower 
concentration. 
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Figure 39. (a) Cell samples that treated with 100 nM of Doxorubicin, brightfield image done by 
using brightfield filter, spectral image by SKY filter which showed the result of uploaded 
Doxorubicin library and merged image between of brightfield and spectral images. (b) The graph 
illustrated Doxorubicin fluorescence wavelength at ~ 592 nm, 670 nm inside the cells, X= 
wavelengths and Y= signal intensity. The blue wavelength displays the area that contains 
Doxorubicin fluorescence which is in the nucleoplasm, while red wavelength showed the spectrum 
of the background region which is cell cytoplasm. (c) The bar graph explained the intensity data 
point variation for peak1 which is higher than peak2, and this variation in consistent with pure, 150 
nM of Doxorubicin results. The intensities here become lower in comparing with pure, 150 nM 
Doxorubicin. 
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Figure 40. (a) Brightfield image is done by brightfield filter of cells that treated with 10 nM of 
Doxorubicin, spectral image by SKY filter which displayed the uploaded Doxorubicin library result 
and merged image of brightfield and spectral images. (b) The graph showed Doxorubicin 
fluorescence wavelength at ~ 592 nm, 670 nm inside the cells, X= wavelengths and Y= signal 
intensity. The blue wavelength illustrated the area that contains Doxorubicin fluorescence which is 
in the nucleoplasm, while red wavelength showed the spectrum of the background area which is in 
the cytoplasm. (c) The bar graph displayed the variation of intensity data point for peak1 that is 
higher than peak2, this variation in consistent with pure, 150, 100 nM of Doxorubicin results. The 
intensities here become lower in comparing with pure, 150, 100 nM Doxorubicin. 
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Figure 41. (a) Cells that treated with 10 nM of Doxorubicin, brightfield image by brightfield filter, 
spectral image by SKY filter which showed the result of uploaded Doxorubicin library and merged 
image of brightfield and spectral images. (b) The graph illustrated Doxorubicin fluorescence 
wavelength at ~ 592 nm, 670 nm inside the cells, X= wavelengths and Y= signal intensity. The blue 
wavelength displayed the region that contains Doxorubicin fluorescence which is in the 
nucleoplasm, while red wavelength explained the spectrum of the background area which is cell 
cytoplasm. (c) The bar graph exhibited the intensity data point variety of peak1 that is higher than 
peak2, this variety in consistent with pure, 150, 100, 10 nM of Doxorubicin results. The intensities 
here also become lower in comparing with pure, 150, 100, 10 nM Doxorubicin. 
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Figure 42. Linear regression analysis of Doxorubicin data by spectral imaging. X= log of 
concentrations in M, Y= average of signal intensity. (a) The graph illustrated the average 
intensities of peak 1 ( ~ 592 nM) vs the concentrations, here we can consider peak 1 because 
of its show excellent linearity at R2= 0.9. While graph (b) explained peak 2 average intensities, 
it showed less linearity in comparing with peak 1 at R2= 0.76. 
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Figure 43. Linear regression analysis of Doxorubicin data by spectral imaging. X= log of 
concentrations in M, Y= average of signal intensity. (a) The graph demonstrated the ratio of 
average intensities for peak 1/peak 2, which has less linearity in comparing with peak 1 and peak 
2 at R2= 0.62. (b) The graph displayed the percentage of the abnormal cells (specifically 
abnormal nucleoplasm) of the samples, the percentage increase with higher concentrations of 
Doxorubicin. 
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3.3.3. Au and Ag NPs Spectral Imaging Result 
For the reason that NPs have no fluorescence, spectral imaging system was conducted by using 
brightfield filter for pure Au and Ag NPs at ~ 536 nm and 420, respectively. These wavelengths 
are in consistent with Spectrophotometer results, and the wavelengths were uploaded and saved as 
libraries files for cell analysis. For Au NPs results, Fig 44a showed the brightfield image which 
was performed by brightfield filter, the spectral image which represents the analysis of uploaded 
wavelengths library of the brightfield image and merged image that combined between brightfield 
and spectral images. The graph in Fig 44b demonstrated the pure Au NPs wavelength at ~ 536 nm. 
The blue wavelength interpreted the area that contains higher wavelength intensity based on 
brighter NPs analysis (bigger particle size) in comparison with a red wavelength which showed 
the region that contains less (smaller particle size). The background displayed the wavelength 
intensity of the NPs background area, which is exhibited by black color spectrum. In addition, the 
bar graph in Fig 44c illustrated the intensity data point variation of Au NPs peak. Fig 45a showed 
the untreated cells images which are negative control, starting with brightfield image by brightfield 
filter, the spectral image which is the result for library analysis of brightfield image and merged 
images between them. Fig 45b showed wavelengths differences between many areas in the cell 
sample which reflect the background in comparing with the positive control (pure Au NPs). 
Forwards, we treat the cells with 100 mg/mL of Au NPs for 18 hrs. Fig 46a explained the 
brightfield image which was done by brightfield filter, a spectral image which is the result of the 
uploaded libraries for the pure Au NPs of brightfield image and merged between brightfield and 
spectral images. Brightfield image revealed Au NPs location in the cell which is in both 
nucleoplasm and cytoplasm. Fig 46b exhibited different wavelengths of the treated cells with 100 
mg/mL at ~ 536 nm, which are consistent with pure Au NPs results. The blue wavelength 
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represented the region that has higher intensity based on brighter NPs analysis (bigger particle 
size), whereas the red spectrum showed the area that contains less (smaller particle size). 
Background displayed as a black color wavelength of the NPs background area. Fig 46c illustrated 
the intensity data point variation of the peak, here we might have an intensity that higher than one 
in the pure result, this is because we work with NPs which are not depending on the concentrations 
anymore; instead, it depends on the particles size. The chart in Fig 47 summarized the Au NPs 
results, the data for spectrum intensity of the pure Au NPs are higher than the negative control 
(untreated cells) sample. However, in the cells which treated with 100 mg/mL of Au NPs, we have 
in some points higher intensity in comparing with pure. This is because the analysis depend on the 
NPs size. The most interesting step when we treated the cells with 100 mg/mL of Ag NPs, Fig 48a 
illustrated the brightfield image which was performed by brightfield filter, the spectral image 
which showed the analysis of uploaded wavelengths library of the brightfield image and merged 
image of between brightfield and spectral images. The graph in Fig 48b displayed the pure Ag NPs 
wavelengths at ~ 420 nm, 762 nm. The pink wavelength interpreted the area that contained the 
core of Ag NPs, while the yellow wavelength showed the region that included shell of Ag NPs. 
Both at the same wavelength but different spectrum shape. The background was showed as a black 
spectrum of the area which contains no Ag NPs. In addition, the bar graph in Fig 48c illustrated 
the intensity data point variation of peak1 which is higher than peak2. As well as Fig 49a showed 
the negative control of untreated cells images, the brightfield image performed by brightfield filter, 
spectral image is the result for library analysis of brightfield image and merged image between 
brightfield and spectral images. Fig 49b displayed wavelengths intensity at ~ 455, 777 nm of 
different areas in the cell sample which reflect the background in comparing with the positive 
control (pure Ag NPs). Fig 49c the bar graph represented the different background intensity 
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between peak1 and peak2 which is the highest.  Moreover, we treated the cells with 100 mg/mL 
of Ag NPs. Fig 50a illustrated the brightfield image which was conducted by brightfield filter, the 
spectral image which is the uploaded libraries result for the pure Ag NPs of brightfield image and 
merged image of brightfield and spectral images. Brightfield image explained Ag NPs location in 
the cell sample which is in the nucleoplasm and cytoplasm. Fig 50b displayed wavelengths 
differences (at ~ 420, 762 nm) between the core spectrum in pink color and the shell in yellow 
within the cell sample, the black spectrum reflected the background area of the NPs. Fig 50c the 
bar graph displayed the intensity wavelengths differences between peak1 which is higher than 
peak2, these data also consistent with pure Ag NPs results. The chart in Fig 51 summarized the 
Ag NPs results, (a) illustrated the average differences between peak1 of pure Ag NPs (at ~420 
nm), negative control (~ 455 nm) and cells that treated with Ag NPs (at 420 nm). Peak2 of pure 
Ag NPs (at ~762 nm), negative control (~ 777 nm) and cells were treated with Ag NPs (~ 762 nm). 
While (b) explained the results of the intensity average of peak1/peak1 of pure Ag NPs which are 
higher than Ag NPs within the cells and negative control.  
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Figure 44. (a) Brightfield image of pure Au NPs done by using brightfield filter, the spectral image 
which is the result for the uploaded library analysis of brightfield image and merged image which 
combine between brightfield and spectral images. (b) The graph demonstrated the wavelengths of 
pure Au NPs at ~ 536 nm, X= wavelengths, and Y= signal intensity. The blue wavelength displayed 
the area that contains higher wavelength intensity based on brighter NPs analysis (bigger particle 
size), while red wavelength showed the region that includes less (smaller particle size). Background 
exhibited as a black color wavelength of the NPs background area. (c) The bar graph exhibited the 
intensity data point variation result for Au NPs peak. 
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Figure 45. (a) Negative control of untreated cells. The brightfield image captured by using 
brightfield filter, spectral image is the result of library analysis of brightfield image and merged 
image which combined between brightfield and spectral images. (b) The graph demonstrated the 
wavelengths of the negative control which reflect the background in comparing with the positive 
control (pure Au NPs). X= wavelengths and Y= signal intensity. (c) The bars indicated the intensity 
variation of the data point for untreated cells. 
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Figure 46. (a) Cell samples which are treated with 100 mg/mL of pure Au NPs, brightfield image 
done by using brightfield filter, the spectral image which showed the result of uploaded Au NPs 
library of brightfield image and merged image between the brightfield and spectral images. (b) The 
graph demonstrated Au NPs wavelength at ~ 536 nm inside the cells, X= wavelengths, and Y= 
signal intensity. The blue wavelength displayed the area that contains high intensity wavelength 
(bigger particle size), while the red wavelength showed less intensity (smaller particle size). (c) The 
bar graph explained the intensity data point variation for Au NPs peak, we may have higher intensity 
data because it depend on the particle size. 
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Figure 47. The chart summarized the Au NPs data results analysis. As is shown, the 
data for the wavelength intensity of the pure Au NPs is higher than the negative control. 
However, in the cells which treated with 100 mg/mL of Au NPs, we have in some 
points higher intensity in comparing with pure. This is because we work with NPs 
which are dependent on the particle size. 
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Figure 48. (a) Brightfield image of pure Ag NPs done by brightfield filter, the spectral image which 
is the analysis result for the uploaded library of brightfield image and merged image of brightfield 
and spectral images. (b) The graph illustrated the wavelengths of pure Au NPs at ~ 420, 762 nm, X= 
wavelengths, and Y= signal intensity. The pink wavelength displayed the intensity of the core area of 
Ag NPs, while the yellow wavelength showed the shell region. Background exhibits as a black color 
spectrum of the NPs background area. (c) The bar graph exhibited the intensity data point variation 
result for peak1 which is higher than peak2. 
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Figure 49. (a) Negative control of untreated cells, brightfield image by brightfield filter, the spectral 
image which is the result for the uploaded library analysis of brightfield image and merged image 
of brightfield and spectral images. (b) The graph illustrated the wavelengths of the negative control 
at ~ 455, 777 nm which we consider it as a background, X= wavelengths, and Y= signal intensity. 
(c) The bar graph exhibited the intensity data point variation for peak1 which is lower than peak2. 
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Figure 50. (a) Cells that treated with 100 mg/mL of Ag NPs, the brightfield image done by 
brightfield filter, the spectral image which is the analysis result for the uploaded library of brightfield 
image and merged image of brightfield and spectral images. (b) The graph illustrated the wavelengths 
of pure Au NPs at ~ 420, 762 nm, X= wavelengths, and Y= signal intensity. The pink wavelength 
demonstrated the intensity of the core area of Ag NPs, whereas yellow wavelength displayed the 
shell region. Background exhibited as a black color spectrum of the NPs background area. (c) The 
bar graph show the intensity data point variation for peak1 which is higher than peak2. This variation 
result is consistent with pure Ag NPs results. 
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Figure 51. Summarized the Ag NPs analysis results, (a) explained the average 
differences between peak1 of pure Ag NPs (at ~420 nm), negative control (~ 455 nm) 
and cells that treated with 100 mg/mL of Ag NPs (at 420 nm). Peak2 of pure Ag NPs 
(at ~762 nm), negative control (~ 777 nm) and treated cells (~ 762 nm). While chart 
(b) demonstrated the results of the peak1/peak1 average of pure Ag NPs, which are 
higher than Ag NPs within the cells and negative control. 
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Chapter 4 
CONCLUSION 
 
The spectral imaging is a powerful technique which can capture the image of the sample and 
displays a spectrum at each pixel of our target. This feature provides the researchers with full and 
details information about the samples in a way that can help to enhance the understanding of many 
topics and questions. For instance, it allows the identification of the exact location and quantity of 
our sample in the cells. In this study, spectral imaging was conducted to test many chemicals 
including rhodamine 6g, doxorubicin, Au NPs and Ag NPs. Spectral imaging was able to identify 
each sample by the spectrum of the molecule; this done by uploading each spectrum of the pure 
chemicals as a library and use it for cells analysis. In addition, spectral imaging was capable to 
identify each molecule within cells by the library of the molecule wavelength. However, we 
observed extra peaks which are not consistent with the spectrophotometer and need to be 
identified.   
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 Appendices 
 
  Rhodamine 3nM MS result 
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Rhodamine 2.5nM MS result 
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Rhodamine 2nM MS result 
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Rhodamine 1.5nM MS result 
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Rhodamine 1nM MS result 
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Rhodamine 0.5nM MS result 
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Rhodamine 0.3nM MS result 
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Rhodamine 0.1nM MS result 
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Rhodamine 3nM LC/MS result 
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Rhodamine 2.5nM LC/MS result 
 
Rhodamine 2.5nM LC/MS result 
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Rhodamine 2nM LC/MS result 
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Rhodamine 1.5nM LC/MS result 
 
 
88 
 
  
Rhodamine 1nM LC/MS result 
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Rhodamine 0.5nM LC/MS result 
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Rhodamine 0.3nM LC/MS result 
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Rhodamine 3nM UV result 
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Rhodamine 2.5nM UV result 
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Rhodamine 2nM UV result 
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Rhodamine 1.5nM UV result 
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Rhodamine 1nM UV result 
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Rhodamine 0.5nM UV result 
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Rhodamine 0.3nM UV result 
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Doxorubicin 3µM MS result 
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Doxorubicin 1.5µM MS result 
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Doxorubicin 1µM MS result 
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Doxorubicin 500nM MS result 
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Doxorubicin 450nM MS result 
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Doxorubicin 300nM MS result 
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Doxorubicin 100nM MS result 
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Doxorubicin 3µM LC/MS result 
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Doxorubicin 1µM LC/MS result 
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Doxorubicin 500nM LC/MS result 
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Doxorubicin 300nM LC/MS result 
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Doxorubicin 3µM UV result 
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Doxorubicin 1µM UV result 
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Doxorubicin 500nM UV result 
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Doxorubicin 300nM UV result 
 
